Amgen extends autoimmune pact with small Michigan biotech
Amgen is going all in on a three-indication collaboration with an Ann Arbor, MI biotech.
The California pharma has elected to move forward with all three autoimmune programs in its $240 million pact with EVOQ Therapeutics, the companies said Wednesday. EVOQ received an undisclosed milestone payment.
The duo initially teamed up in January 2021. Since then, the startup from the University of Michigan and Lawrence Livermore National Laboratory has also allied with the nonprofit JDRF on type 1 diabetes and, in recent weeks, with Gilead for rheumatoid arthritis and lupus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.